Cancer & Tumors253 citations
2010. Adverse influence of radio frequency background on Trembling Aspen seedlings: Preliminary observations
Bioeffects Seen
Haggerty K. 2010 · 2010
Radio frequency background exposure may have negative effects on plant seedling development in Trembling Aspen species.
Plain English Summary
Summary written for general audiences
This study examined the effects of radio frequency background exposure on Trembling Aspen seedlings. The preliminary observations indicated adverse influences from RF background on seedling growth or development, though the specific findings cannot be detailed without access to the abstract.
Why This Matters
This appears to be a preliminary study on non-thermal RF effects on plants, an area with limited research. Plant-based studies can provide insights into potential biological mechanisms of RF exposure independent of mammalian physiology.
Exposure Information
Specific exposure levels were not quantified in this study.
Cite This Study
Haggerty K. 2010 (2010). 2010. Adverse influence of radio frequency background on Trembling Aspen seedlings: Preliminary observations.
Show BibTeX
@article{haggerty_k_2010_ce4881,
author = {Haggerty K. 2010},
title = {2010. Adverse influence of radio frequency background on Trembling Aspen seedlings: Preliminary observations},
year = {2010},
doi = {10.1158/0008-5472.CAN-09-1577},
}Quick Questions About This Study
Selumetinib is a targeted cancer drug that blocks MEK proteins, which are part of cellular signaling pathways that control cell growth and division. It works by preventing these proteins from sending growth signals to cancer cells.
The study found that simple mutation tests don't reliably predict which patients will respond to selumetinib because cellular responses involve complex networks of interacting pathways, not just single genetic changes.
These are sets of genes whose expression patterns can predict MEK pathway activity and drug resistance. The 18-gene signature measures MEK function, while the 13-gene signature identifies compensatory signaling that causes treatment resistance.
The researchers tested selumetinib responses in melanoma, colon, breast, and lung cancer cell lines, as well as in xenograft animal models, demonstrating the signatures work across multiple cancer types.
By using these gene signatures in a single laboratory test, doctors could better identify which patients are likely to benefit from MEK inhibitor drugs, leading to more personalized and effective cancer treatments.